Compare VLRS & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VLRS | ARVN |
|---|---|---|
| Founded | 2005 | 2015 |
| Country | Mexico | United States |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 675.9M | 600.2M |
| IPO Year | 2013 | 2018 |
| Metric | VLRS | ARVN |
|---|---|---|
| Price | $5.72 | $7.72 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 16 |
| Target Price | $9.04 | ★ $13.93 |
| AVG Volume (30 Days) | 383.6K | ★ 650.9K |
| Earning Date | 10-26-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 58.84 |
| EPS | N/A | ★ 1.70 |
| Revenue | N/A | ★ $262,600,000.00 |
| Revenue This Year | $20.91 | $12.76 |
| Revenue Next Year | $7.79 | N/A |
| P/E Ratio | ★ N/A | $4.45 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.59 | $6.74 |
| 52 Week High | $10.80 | $14.22 |
| Indicator | VLRS | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 28.24 | 50.95 |
| Support Level | N/A | $6.74 |
| Resistance Level | $7.15 | $7.74 |
| Average True Range (ATR) | 0.21 | 0.34 |
| MACD | -0.04 | 0.09 |
| Stochastic Oscillator | 14.71 | 91.90 |
Controladora Vuela Compania de Aviacion SAB de CV is a low-cost airline flying to Mexico, the United States, Central, and South America. It uses promotional fares to stimulate demand, and the base fares are priced to compete with long-distance bus fares in Mexico. Revenues from the air transportation of passengers are recognized earlier when the service is provided or when the non-refundable ticket expires on the date of the scheduled travel. Non-passenger revenues include revenues generated from other non-passenger services and cargo services. The Company has two geographic areas identified as domestic (Mexico) and international (United States of America, Central America, and South America).
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.